Replies to post #38649 on ProText Mobility Inc (TXTM)

[upanddown66]

what has this to do with TXTM ?

[highlandernew]

This news is for Plandai LONDON? Plandai BOCA RATON gets NOTHING?

Plandai BOCA RATON shareholders are the GUINEA PIGS of PLPL?

What are your thoughts about this?

[badbadbad]

Look what happened to BLDV after they announced final stages of obtaining an MMJ license. The stock has blown up. &, Co. has 4.76 BILLION shs OS


Same will happen with TXTM



Share Structure
Market Value1 $7,616,937 a/o Apr 20, 2017
Authorized Shares 5,799,499,999 a/o Apr 10, 2017
Outstanding Shares 4,760,585,689 a/o Apr 10, 2017
-Restricted 209,636,711 a/o Apr 10, 2017
-Unrestricted 4,550,948,978 a/o Apr 10, 2017
Held at DTC 2,417,795,039 a/o Apr 10, 2017
Float 4,550,948,978 a/o Sep 30, 2016
Par Value 0.001



Blue Diamond Ventures, Inc. (OTC Pink: BLDV) is engaged as a business development company, which focuses on agriculture, renewable energy, natural holistic products, and botanicals. Shares of the business development company are surging 200%, through early trading on Thursday, April 20, 2017. Over the past three months, Blue Diamond Ventures, Inc. has seen average daily volume of 17.86 million shares. However, volume of 753.1 million shares or dollar volume of $903,720, has already exchanged hands on Thursday.
Shares of Blue Diamond Ventures, Inc. are soaring today, after the company announced it is launching an international cannabis project, through a partnership with Canadian company, Alternative Medical Solutions, Inc. The Canadian company is in the final stages to obtain a license to grow, market, and distribute medical marijuana through Health Canada.

[badbadbad]

Phytofare Cannabis is the extract Cannabis Biosciences will develop under a SA mmj license. That is 100% owned by TXTM. While PLPL runs Senteeko and owns the 100,000 sq ft manufacturing facility, TXTM has the worldwide exclusive license to develop Phytofare for pharmaceutical applications, and includes the rights to the technology platform and extraction processes developed by PLPL. The corporate profile of the company is attached below.

-------- Original Message --------
Subject: please reply
From:
Date: Mon, May 15, 2017 6:54 pm
To: [e-mail]

please clarify who owns phytofare cannabis




Corporate Profile:

Protext Mobility (publicly traded under TXTM), operates two wholly owned subsidiaries; Plandai Biotechnology South Africa (SA) and Cannabis Biosciences, Inc. The Company is engaged in the research and clinical testing of “bioceutical” products—all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions.

Through its wholly owned subsidiary Plandai Biotechnology SA, the Company has the exclusive worldwide license to develop pharmaceutical applications and products using the Phytofare® catechin complex, which was developed by Plandaí Biotechnology, Inc. Phytofare® is a highly bioavailable extract produced from live green tea leaves. Our initial product, Phytofare® Catechin Complex, has been clinically shown to have 10 times greater bioavailability over generic catechin extracts. What this means is that Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours. Plandaí grows green tea on its 7,500 acre Senteeko estate in South Africa, where it produces the proprietary Phytofare® catechin extract in-house, allowing the Company a continuity of supply as well as quality control throughout the entire process. Targeted applications for the Company's products include arthritis, inflammation, anti-viral, and diabetes-related metabolic syndromes.

Cannabis Biosciences was formed and incorporated in 2013 to legally develop non-psychoactive medicines from live cannabis plant. Using our proprietary processing and extraction technology platform, the company intends to commence investigations in conjunction with independent researchers to develop and validate a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The expectation is that the resultant extract will have similar, superior bioavailability of other Phytofare® extracts with the added benefit of being non-psychoactive. Several third-party investigations have shown that the precursor acid forms THC-A and THC-B in live cannabis leaf are inherently non-psychoactive and that the process of drying and heating the leaf metabolizes these acid forms into THC, a chemical that triggers the euphoria sought after by recreational users. The Company’s investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential. The acquisition of Cannabis Biosciences by Protext properly aligns our pharmaceutical research under one roof, allowing us to further our cannabis studies as we strive to create a cannabis extract that can increase the well-being and potentially improve the lives of so many people. The Company is actively pursuing government licenses and permits, which is anticipated to be issued in Q2, 2017 that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract.




Plandai Biotechnology SA:

Background: Phytofare, Green tea and metabolic syndrome
Metabolic syndrome is a cluster of conditions — increased blood pressure, a high blood sugar level, excess body fat around the waist and abnormal cholesterol levels — that occur together, increasing your risk of heart disease, stroke and diabetes. Diabetes type 2 is a long term metabolic disorder that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss. Symptoms may also include increased hunger, feeling tired, and sores that do not heal. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations.

While low vitamin D levels are associated with an increased risk of diabetes, type 2 Diabetes is partly preventable by maintaining a normal weight, exercising regularly, and eating properly through dietary changes. When blood sugar levels are not adequately lowered, the medication Metformin is typically recommended to decrease liver glucose production; and can cause considerable side effects.

Levels of type 2 Diabetes have increased markedly since 1960 in parallel with obesity, and as of 2013 there were approximately 368 million people diagnosed with the disease compared to around 30 million in 1985. Typically it begins in middle or older age, although rates of type 2 diabetes are increasing in young people and is associated with a ten-year-shorter life expectancy and a poor quality of life.

In looking for a natural solution, epidemiological evidences indicate that populations with a high intake of green tea catechins benefit in terms of body weight, body fat, the balance of insulin and glucagon, maintaining blood glucose, and cardiovascular health. This is particularly true considering the strong research data from in vitro and animal studies where actions from green tea catechins have shown decreased carbohydrate absorption, decrease hepatic glucose production (The inability of insulin to suppress hepatic glucose production is a key defect found in type 2 diabetes) and increased insulin sensitivity (the relationship between how much insulin needs to be produced in order to deposit a certain amount of glucose).

However, transferring the scientific findings from in vitro and animal studies to a delivery system that benefits humans has always been met with metabolism and degradation issues; as well as the amount of catechins that are transferred to the blood plasma and the time they remain there. Furthermore, to partially achieve this success high dosage of catechins is required, producing toxicity and side effects.

Phytofare® catechin complex is a highly bioavailable complex of all 8 catechins found in green tea that have been clinically researched to efficiently transfer the antioxidants into the blood plasma, where they remain for more than 24 hours. Furthermore, the daily dosage has been established at 10 times less than generic green tea, thereby delivering an active antibiotic without toxicity or side effect issues.

To clinically prove these antidiabetic benefits in humans, Protext will undertake with Phytofare® catechins, delivered in a capsule, a human clinical trial consisting of an independent double blind clinical study in Q3 2017, commencing with a bioavailability study in May 2017 to determine dosage; with the objective to commercialize an affordable solution in what is a multibillion dollar global market opportunity for the prevention and containment of metabolic syndrome causes.


Cannabis Biosciences Inc:

Medicinal Non-psychoactive Cannabis
Protext has acquired ownership of Cannabis Biosciences, along with the rights to undertake research and development; formulate and commercially sell and distribute Phytofare® cannabis medicines. Acquired by Plandai Biotechnology Inc., www.plandaibiotech.com the agreement is supported by scientifically proven manufacturing and formulation protocols for producing phytonutrient complexes from live plant materials. This includes a supply agreement for the global commercialization Phytofare® catechin complex produced from live green tea at Plandai’s Senteeko tea, South Africa. The complex is delivered as highly bioavailable catechin extract and sold as an ingredient or formulated into oral delivery systems for human and animal wellness benefits.

Independent oral and topical human clinical studies conducted by North West University Pharmacology department (Grobler et al., June 2015) established Phytofare® catechin complex addressed all the botanical bioavailability barriers (Ming et al., Molecular Pharmaceutics Vol4 no 6) of solubility, permeability, metabolization, excretion, target uptake and disposition. The results showed more than twelve times greater bioavailability and the presence after 24 hours of all eight green tea catechins in the bloodstream, compared to only two catechins in the generic extract which washed out after 6 hours.

Background
In September 2014, the Uruguay Ministry of Health granted a license to Plandai Biotechnology Uruguay, SA; a private Uruguay company, regulating and authorizing the growing, harvesting and processing of live cannabis; extending to the recovery and formulation of Phytofare® cannabinoid complex including clinical investigations. In May 2015, an additional license was granted by the Institute of Regulation and Control of Cannabis (IRCCA), approving and authorizing the project under the Marihuana and Derivates Law 19.172, Decree No.46/2015, Articles 6 and 9. Combined, these approvals allowed Plandai to establish a scientific platform to develop cannabis medicines in the treatment of cancers, pain and neurodegenerative diseases. The project was suspended in 2015 due to lack of infrastructure in Uruguay to implement this model.

Meanwhile during the same period in South Africa the company was aligned as part of the delegation supporting the Ambrosini private members bill submitted in 2013 to the Portfolio Committee in the South African Parliament. This followed meetings with the Director General of Health, South Africa in June 2014; and submission of an application to conduct research and development for cannabis medicines as provided for under Section 22A (9) of the Medicines and Related Substance Act 1965.

Following South Africa's Governmental approval for the sale of cannabis medicines in that country in February 2017, the company was advised by the Deputy-Director of Health in April 2017 that the government had approved the application for the issuance of a Cannabis research and development license subject to inspection of the company’s South Africa research and development facilities, expected in May 2017. This license would allow the growing, harvesting, processing and the recovery of a Phytofare® cannabinoid complex; extending to analysis, product profiling and clinical investigation, followed by commercialization.

Understanding Cannabis
The major problem in the current world of medical marijuana is the inability of the industry to deliver botanical cannabinoid agents with therapeutic action in a validated dosage and without psychotropic side effects.

As the industry of medical marijuana has rapidly grown over the past few years in the United States and many other parts of the world, so have the scientific challenges and responsibilities. Numerous, largely unregulated, botanical cannabis products sold through licensed dispensaries have entered the market. Medicinal applications range from formulated foods, liquids, capsules, vapour pens and inhalers, or simply smoking the dried flower. The claims are disparate, unsupported by clinical trials, and fail to take into account varying dosage levels or differences in chemical values of the different strains.

This new industry has not addressed or overcome multiple challenges associated with the development of a safe wellness product. These products, targeted for disease prevention rather than recreational use, still rely mainly on psychoactive oral administration as the only viable route. The undesirable consequences are disturbing and heavily stigmatized in most societies.

For cannabinoids to become an approved botanical drug, the questions of psychoactivity, isomeric compatibility, solubility, permeability, metabolization, excretion, target tissue uptake, residence time and disposition must be clinically addressed.

The plant Cannabis sativa produces over 421 chemical compounds including 80 terpeno-phenol compounds (phytocannabinoids) that have not been detected in any other plant. Currently commercial attention has been focused on producing extracts of ??- tetrahydrocannabinol (??- THC) which is the most psychotropic component and rapidly metabolizes in the body to a number of oxygenated products; but specifically binds to the G-protein-coupled CB1and CB2 neuron receptors.

Our strategy is to improve the efficacy through delivering a complex of highly bioavailable non-psychoactive cannabinoids and polyphenols; and by eliminating the psychotropic side effects of ??- tetrahydrocannabinol by retaining it in its natural form: ??- tetrahydrocannabinol acid (??-THCA and (??-THCB), cannabidiolic acid (CBDA) and ?? tetrahydrocannabivarin (??-THCV). Research shows that these compounds exert multiple actions through mechanisms and together with cannabidiol (CBD), delivers several safe positive pharmacological effects in inflammation, diabetes and cancer,

CBD is the only cannabinoid to antipsychotic effects and is associated with fewer adverse effects compared to prescribed antipsychotic medicines. This cannabinoid exerts neuroprotective actions relevant in the treatment and prevention and apoptotic signalling of neuro-degenerative diseases including Alzheimer’s, Parkinson’s and Huntingdon.

Prior research with non-psychotropic phytocannabinoids have shown multiple pharmacological effects with analgesic, anti-inflammatory, antioxidant, neuroprotective and prop apoptotic modulation with different mechanisms of action to the central nervous system and in the periphery.

Scientific Approach
Methodologies and manufacturing disciplines for producing the Phytofare® extract and recovery of cannabis oil are specific to Plandai sciences and technologies.
Based on all the scientific evidence, the company intends to produce a complex of the entire plant phytonutrients, including cannabinoids, cannabinoid acids and polyphenols; delivered in sub-micron and nano lipophilic particles with high human isomeric identity. (The cannabis oil recovered as a separate commodity). The resultant extract will be entrapped in liposome phospholipid molecule produced from sunflower oil that will carry and protect the antioxidant to the blood plasma. This ensures high bioavailability, efficacy and protection of the antioxidant through the stomach and liver acids.
Based on published science, Phytofare® cannabinoid complex should not exhibit any psychoactive activity because the conditions for the formation of THC from THC-A and THC-B acids will not be introduced, and where it is already proven that the acids in their natural state are not psychoactive. (American Herbal Pharmacopoeia Cannabis Inflorescence 2013 Page 34)
Commercialization
The business model is to produce a Phytofare® dietary supplement containing a complex of non-psychoactive cannabinoids, entrapped in liposome and delivered for oral administration. Following the initial profiling, bioavailability, dosage levels and the absence of psychoactivity will be established. In turn, the company will seek declassification of the extract from the Government of South Africa from a code 6-controlled substance to a code 0 and thereby allowing the Company global reach for licensing and sale of cannabis product.


Chairman & CEO: Roger Baylis Duffield
Mr. Duffield has a significant background in the development and management of start-ups, private and public companies, in the United States, Europe and South Africa. Currently, Mr. Duffield serves as CEO of Protext Mobility as well as Chairman of Plandai Biotechnology Inc., a USA public company with operations in South Africa. He also serves as the non-executive chairman of the Dunn Roman group of companies. In 2002, Mr. Duffield cofounded the Plandai group of companies, which is now comprised of considerable interests in biopharmaceuticals in South Africa, including the 7500 acre Senteeko green tea estate. He has an extensive background with published scientific research and development of Plandai sciences and bioavailable botanical extracts through the actions of cavitation and sonoluminescence relating with live plant materials and emulsions. The Plandai science platform involves contributions from numerous academic institutions and research laboratories.

Mr. Duffield was awarded in 1997 an Honorary Nuclear Doctorate by the Russian Academy of Natural Sciences and a further Honorary Doctorate in Material Sciences by the European Natural Sciences. In 2001 the Foundation for International Services, California granted recognition of a BSc qualification in Chemical Engineering. During the period 1990 through 2002 Mr. Duffield both founded and managed two USA public companies involved with new sciences relating to hydrocarbons, emulsions and fuel cells supported through powder metallurgy. Extensive published research has been undertaken with numerous academic institutions through the world, including USA, Europe, Russia, Siberia and South Africa. Mr. Duffield also has an extensive background in the farming of sub-tropical fruits and green tea when he owned and operated farms in South Africa.



Company Website:
http://www.protextm.co/

Social Media:
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/